ReviewActa neuropathologica2010
Biomarker discovery for Alzheimer's disease, frontotemporal lobar degeneration, and Parkinson's disease.
Review in Acta neuropathologica, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed.
- Precision Medicine for Preventing Alzheimer's Disease: Analysis of the ADAPT Study.Journal of Alzheimer's disease : JAD · 2023Trial
- A Precision Medicine Model for Targeted NSAID Therapy in Alzheimer's Disease.Journal of Alzheimer's disease : JAD · 2018Trial
- The ketogenic diet in Parkinson's disease: a potential therapeutic strategy.Pharmacological reports : PR · 2025Review
- Understanding Tau pathology: Insights from animal models.Zoological research · 2025Review
- Analysis and interpretation of inflammatory fluid markers in Alzheimer's disease: a roadmap for standardization.Journal of neuroinflammation · 2025Review
- Longitudinal decline in DAT binding in Parkinson's disease: connections with sleep disturbances.BMC medicine · 2024Article
- Review
- Charting the Next Road Map for CSF Biomarkers in Alzheimer's Disease and Related Dementias.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2023Review
- Smelling the Disease: Diagnostic Potential of Breath Analysis.Molecular diagnosis & therapy · 2023Review
- The Future of Precision Medicine in the Cure of Alzheimer's Disease.Biomedicines · 2023Review
- CSF IL-8 Associated with Response to Gene Therapy in a Case Series of Spinal Muscular Atrophy.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2023Article
- Tau in the Pathophysiology of Parkinson's Disease.Journal of molecular neuroscience : MN · 2021Review
- Biomarkers and Precision Medicine in Alzheimer's Disease.Advances in experimental medicine and biology · 2021Article
- Article
- A proteomic signature for dementia with Lewy bodies.Alzheimer's & dementia (Amsterdam, Netherlands) · 2019Article
- Cutting Edge Methods for Non-Invasive Disease Diagnosis Using E-Tongue and E-Nose Devices.Biosensors · 2017Review
- PRECISION MEDICINE - The Golden Gate for Detection, Treatment and Prevention of Alzheimer's Disease.The journal of prevention of Alzheimer's disease · 2016Article
- Network-driven plasma proteomics expose molecular changes in the Alzheimer's brain.Molecular neurodegeneration · 2016Article
- Expanding the Repertoire of Biomarkers for Alzheimer's Disease: Targeted and Non-targeted Approaches.Frontiers in neurology · 2015Review
- Plasma Inflammatory Factors Are Associated with Anxiety, Depression, and Cognitive Problems in Adults with and without Methamphetamine Dependence: An Exploratory Protein Array Study.Frontiers in psychiatry · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Ante-mortem diagnosis of neurodegenerative disorders based on clinical features alone is associated with variable sensitivity and specificity, and biomarkers can potentially improve the accuracy of clinical diagnosis. In patients suspected of having Alzheimer's disease (AD), alterations in cerebrospinal fluid (CSF) biomarkers that reflect the neuropathologic changes of AD strongly support the diagnosis, although there is a trade-off between sensitivity and specificity due to similar changes in cognitively healthy subjects. Here, we review the current approaches in using CSF AD biomarkers (total tau, p-tau(181), and Abeta42) to predict the presence of AD pathology, and our recent work using multi-analyte profiling to derive novel biomarkers for biofluid-based AD diagnosis. We also review our use of the multi-analyte profiling strategy to identify novel biomarkers that can distinguish between subtypes of frontotemporal lobar degeneration, and those at risk of developing cognitive impairment in Parkinson's disease. Multi-analyte profiling is a powerful tool for biomarker discovery in complex neurodegenerative disorders, and analytes associated with one or more diseases may shed light on relevant biological pathways and potential targets for intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.